News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Study of Medtronic, Inc. (MDT) Endeavor® Drug-Eluting Stent Demonstrates Long-Term Advantages over Taxus® DES



11/9/2011 10:16:24 AM

SAN FRANCISCO--(BUSINESS WIRE)--New research findings released at TCT 2011 show that the Endeavor® zotarolimus-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) outperformed Boston Scientific Corp.’s Taxus® paclitaxel-eluting stent on standard measures of safety and efficacy through five years of clinical follow-up.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES